Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model
Por:
Monroy-García A., Gómez-Lim M.A., Weiss-Steider B., Hernández-Montes J., Huerta-Yepez S., Rangel-Santiago J.F., Santiago-Osorio E., Garcia, MDM
Publicada:
1 feb 2014
Categoría:
Virology
Resumen:
HPV L1-based virus-like particles vaccines (VLPs) efficiently induce temporary prophylactic activity through the induction of neutralizing antibodies; however, VLPs that can provide prophylactic as well as therapeutic properties for longer periods of time are needed. For this purpose, we generated a novel HPV 16 L1-based chimeric virus-like particle (cVLP) produced in plants that contains a string of T-cell epitopes from HPV 16 E6 and E7 fused to its C-terminus. In the present study, we analyzed the persistence of specific IgG antibodies with neutralizing activity induced by immunization with these cVLPs, as well as their therapeutic potential in a tumor model of C57BL/6 mice. We observed that these cVLPs induced persistent IgG antibodies for over 12 months, with reactivity and neutralizing activity for VLPs composed of only the HPV-16 L1 protein. Efficient protection for long periods of time and inhibition of tumor growth induced by TC-1 tumor cells expressing HPV-16 E6/E7 oncoproteins, as well as significant tumor reduction (57 %), were observed in mice immunized with these cVLPs. Finally, we discuss the possibility that chimeric particles of the type described in this work may be the basis for developing HPV prophylactic and therapeutic vaccines with high efficacy. © 2013 Springer-Verlag Wien.
Filiaciones:
Monroy-García A.:
Univ Nacl Autonoma Mexico, UMIEZ, Fac Estudios Super Zaragoza, Lab Inmunobiol,Unidad Invest Diferenciac Celular, Mexico City 09230, DF, Mexico
Gómez-Lim M.A.:
Unidad Irapuato, Centro de Investigación y de Estudios Avanzados (CINVESTAV), Guanajuato, Mexico
Weiss-Steider B.:
Univ Nacl Autonoma Mexico, UMIEZ, Fac Estudios Super Zaragoza, Lab Inmunobiol,Unidad Invest Diferenciac Celular, Mexico City 09230, DF, Mexico
Hernández-Montes J.:
Univ Nacl Autonoma Mexico, UMIEZ, Fac Estudios Super Zaragoza, Lab Inmunobiol,Unidad Invest Diferenciac Celular, Mexico City 09230, DF, Mexico
Huerta-Yepez S.:
Unidad de Investigacion en Enfermedades Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico
Rangel-Santiago J.F.:
Unidad de Investigacion en Enfermedades Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico
Santiago-Osorio E.:
Univ Nacl Autonoma Mexico, UMIEZ, Unidad Invest Diferenciacio Celular & Canc FES Za, Mexico City 09230, DF, Mexico
Garcia, MDM:
Univ Nacl Autonoma Mexico, UMIEZ, Fac Estudios Super Zaragoza, Lab Inmunobiol,Unidad Invest Diferenciac Celular, Mexico City 09230, DF, Mexico
|